Results 71 to 80 of about 967,275 (342)

New Technologies for Influenza Vaccines

Microorganisms, 2020
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to ...
S. Rockman, K. Laurie, Simone Parkes, A. Wheatley, I. Barr   +4 more
semanticscholar   +1 more source

Mitigation Strategies for Pandemic Influenza A: Balancing Conflicting Policy Objectives [PDF]

, 2011
Mitigation of a severe influenza pandemic can be achieved using a range of interventions to reduce transmission. Interventions can reduce the impact of an outbreak and buy time until vaccines are developed, but they may have high social and economic ...
Heesterbeek, J.A.P., Klinkenberg, Don, Anderson, R.M., Hans Heesterbeek, Heesterbeek, Hans, Roy M. Anderson, Klinkenberg, D, Hollingsworth, TD, Hollingsworth, T. Déirdre, Klinkenberg, D., Dep Gezondheidszorg Landbouwhuisdieren, Strategic Infection Biology, Anderson, RM, Roy M Anderson, T. Déirdre Hollingsworth, Don Klinkenberg, Heesterbeek, H, T Déirdre Hollingsworth, Hollingworth, T.D., Anderson, Roy M.   +19 more
core   +1 more source

Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for ‘Universal’ Influenza Vaccines

, 2021
Influenza virus remains a serious public health burden due to ongoing viral evolution. Vaccination remains the best measure of prophylaxis, yet current seasonal vaccines elicit strain-specific neutralizing responses that favor the hypervariable epitopes ...
Maya Sangesland, Daniel Lingwood
core   +1 more source

Viral Infection‐Inspired Autonomous Detection of Fusion‐Competent Viruses for Screening and Environmental Surveillance

Advanced Materials, EarlyView.
Inspired by viral entry mechanisms, the FUSION assay enables autonomous detection of respiratory viruses via membrane fusion–triggered CRISPR‐Cas13a activation. VEACON selectively fuses with fusion‐competent viruses, triggering fluorescence within confined vesicles.
Jae Chul Park, Yidam Song, Hyun‐Woo Choi, Jaeuk Sung, Harin Jin, WonSeok Gwak, Kirim Yoo, Soohwang Lee, Jongeon Park, Jeongmin Kim, Hye‐Jun Jo, Jahyun Koo, Youngdo Jeong, Kwan Hyi Lee, Seung‐Jung Kee, Hojun Kim   +15 more
wiley   +1 more source

Sociocultural concepts of pandemic influenza and determinants of community vaccine acceptance in Pune, India [PDF]

, 2015
Vaccines are considered one of public health’s greatest achievements. Yet, public concerns and hesitancy towards acceptance of vaccines has been noted around the world for various vaccines.
Sundaram, Neisha
core   +1 more source

Advances in Nucleic Acid Universal Influenza Vaccines

Vaccines
Currently, vaccination with influenza vaccines is still an effective strategy to prevent infection by seasonal influenza virus in spite of some drawbacks with them.
Liang Xu, Weigang Ren, Qin Wang, Junwei Li   +3 more
doaj   +1 more source

Development of cross-protective influenza A vaccines based on cellular responses

Frontiers in Immunology, 2015
Seasonal influenza vaccines provide protection against matching influenza A virus (IAV) strains mainly through the induction of neutralizing serum IgG antibodies. However, these antibodies fail to confer a protective effect against mismatched IAV.
Peter Christiaan Soema, Peter Christiaan Soema, Elly evan Riet, Gideon eKersten, Gideon eKersten, Jean-Pierre eAmorij   +5 more
doaj   +1 more source

Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems

Advanced Science, EarlyView.
By integrating data from in vitro, ex vivo, and in vivo models, our research identifies the MARV glycoprotein as a remarkable hemorrhagic factor, filling a major gap in this important field. It also provides practical experimental tools for the basic research on viral pathogenesis and applied research aimed at antiviral intervention for hemorrhagic ...
Ting Yao, Hang Liu, Yanfeng Yao, Wei Deng, Jiawen Sun, Zhenyu Kang, Ashaq Ali, Chao Shan, Zhiming Yuan, Fei Deng, Hualin Wang, Yun‐Jia Ning   +11 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses

Scientific Reports, 2021
While vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in ...
James D. Allen, Ted M. Ross
doaj   +1 more source